20h agoSeeking AlphaNEUTRAL 50Earnings
Caris Life Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-11. The following slide deck was published by Caris Life Sciences, Inc.
Archived explainer. For the current picture see today's CAI page.
Why Is CARIS LIFE SCIENCES (CAI) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 12, 2026 at 10:05 AM ET · reviewed against 1 wire stories
CARIS LIFE SCIENCES (CAI) is drawing unusual attention today. Our newswire has captured 1 story on CAI across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
CAI stock is moving today, down approximately 5.1% in early trading, following the release of its Q2 2026 earnings presentation and a revised sales guidance. The stock opened at $23.11 and has since declined to $22.09, trading below its 52-week high of $42.50. The move reflects a mix of strong recent performance and the market’s response to updated guidance and broader sector dynamics.
What Happened
Caris Life Sciences published its Q2 2026 earnings call presentation on August 11, 2026. The company raised its full-year 2026 sales guidance to a range of $1.030B to $1.040B, up from the previous $1.000B to $1.020B. This new guidance exceeds the current estimate of $1.003B. Q2 sales came in at $263.712M, beating the $238.125M estimate. The company also announced it will offer in-house PTEN immunohistochemistry testing following recent FDA approvals. These developments were accompanied by a positive note from Evercore ISI Group, which maintained an Outperform rating and raised its price target to $26.
What The Data Shows
The stock has gained 50.1% over the last eight sessions, rising from $15.61 to $23.44. The current intraday session shows a volatile start, with the stock peaking at $23.30 before falling to $22.02. Trading volume of 0.3M shares is below the 3-month average. On the fundamentals, CAI has a market cap of $5.7B, a P/E ratio of 61.6, and trailing twelve-month revenue growth of 85.4%. Insiders have been active, with one buy reported in the last 90 days totaling $990K.
What To Watch
The stock is set to continue its earnings-driven narrative. Investors will be watching for further updates on the company’s execution against its revised sales guidance and the impact of its new FDA-approved diagnostic offerings.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CAI by the numbers
7 sessions: +36.70%Coverage: 1 stories / 1 sourcesAI sentiment: 50/100 (mixed)Mkt cap: $5.7BP/E: 61.652w: $14.19 to $42.50
The headlines behind the move
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on CAI: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CAI move explainers: 2026-08-12 · 2026-08-07 · 2026-08-06